

Virginia's Department of Medical Assistance Services
Pharmacy and Therapeutics Committee Meeting
600 East Broad Street – 7th Floor Conference Rooms
Richmond, Virginia 23219
Thursday, September 19, 2019 - 10:00 a.m.

Comments from DMAS Chief Medical Officer	Chethan Bachireddy, MD, CMO, Chair
Call to Order	Dr. Bachireddy
Approval of Minutes from March 29, 2019 Meeting	P&T Committee Members TAB 2
Drug Utilization Review (DUR) Board Update	Rachel Cain, PharmD
PDL Management	P&T Committee Members

• **PDL Phase II – New Drug Review (Therapeutic Class)**

Brand Drugs

- Tremfya[®], Skyrizi[®] (Cytokine And CAM Antagonists) *(Closed class)* **TAB 3**
- Mayzent[®], Mavenclad[®] (Multiple Sclerosis Agents) **TAB 4**
- Duobrii[™] (Psoriasis, Topical) **TAB 5**
- Adhansia XR[™], Jornay PM[™], Sunosi[™], (Stimulants And Related Agents) *(Closed class)* **TAB 6**

Generics Drugs or New Dosage Forms

- benzhydrocodone/acetaminophen (*authorized generic for Apadaz[®]*) (Analgesics, Narcotics Short)
- aspirin/omeprazole (*generic for Yosprala[®]*) (Platelet Aggregation Inhibitors) *(Closed Class)*
- naftifine (*generic for Naftin[®] Gel*) (Antifungals, Topical)
- febuxostat (*generic for Uloric[®]*) (Antihyperuricemics)
- solifenacin succinate (*generic for Vesicare[®]*) (Bladder Relaxant Preparations)

• **PDL Phase I – Annual Review: Therapeutic Drug Classes with Updates**

Antivirals

- Hepatitis C Agents *(Closed Class)* **TAB 7**

Cardiac Medications

- Angiotensin Modulators II (Direct Renin Inhibitors & combination products) **TAB 8**
- Beta Blockers (*includes combination products*) **TAB 9**
- Lipotropics, Other (*includes Bile Acid Sequestrants, Cholesterol Absorption Inhibitor agents, Fibric Acid derivatives, Microsomal Triglyceride Transfer Protein Inhibitors, Niacin derivatives, Oligonucleotide Inhibitors and Omega 3 agents*) **TAB 10**
- Lipotropics, Statins **TAB 11**
- PAH Agents (oral, inhaled & injectables) **TAB 12**

Central Nervous System

- Anticonvulsants **TAB 13**
- Antidepressants, SSRI **TAB 14**
- Antipsychotics (*includes oral and long-acting injectables*) *(Closed Class – LA injectables only)* **TAB 15**
- Sedative Hypnotics **TAB 16**

Dermatological Agents

- Immunomodulators, Atopic Dermatitis **TAB 17**

Endocrine & Metabolic Agents

- Glucocorticoids, Oral **TAB 18**
- Hereditary Angioedema (HAE) **TAB 19**

Gastrointestinal

- GI Motility, Chronic **TAB 20**
- Ulcerative Colitis **TAB 21**

Ophthalmics

- Anti-Inflammatory Agents (*includes Ophthalmic NSAIDS & Corticosteroids*) **TAB 22**
- Glaucoma Agents (*includes Alpha-2 Adrenergics, Beta-blockers, Carbonic Anhydrase Inhibitors, Prostaglandin Inhibitors*) **TAB 23**

Respiratory

- Anti-Allergens, Oral **TAB 24**
 - Epinephrine, Self-Injected **TAB 25**
 - Glucocorticoids (*includes nebulized solns, metered dose inhalers & combos*) (*Closed Class*) **TAB 26**
- **PDL Phase I – Annual Review: Therapeutic Drug Classes without Updates (reviewed by the Department)**

Antibiotics/Anti-Infectives

- Antibiotics, Vaginal

Blood Modifiers

- Bile Salts
- Phosphate Binders

Cardiac Medications

- Angiotensin Modulators (*includes ACEs, ARBs, and combination products*)
- Antihypertensives, Sympatholytics (*Closed Class*)
- Calcium Channel Blockers (*includes dihydropyridine and non-dihydropyridine agents*)

Central Nervous System

- Alzheimer's Agents
- Antidepressants, Other

Dermatological Agents

- Steroids, Topical

Endocrine & Metabolic Agents

- Growth Hormones (*Closed Class*)
- Progestins for Cachexia

Gastrointestinal

- Antiemetic/Antivertigo Agents
- H. pylori Agents
- Histamine-2 Receptor Antagonists (H-2RA)
- Proton Pump Inhibitors

Genitourinary

- BPH Agents (*includes Alpha Blockers, Androgen Hormone Inhibitors and Phosphodiesterase (PDE) 5 Inhibitors for BPH treatment*)
- Bladder Relaxants

Ophthalmics

- Allergic Conjunctivitis (*includes Ophthalmic Antihistamines & Mast Cell Stabilizers*)
- Antibiotics
- Antibiotic/Steroid Combinations

Respiratory

- Antibiotics, Inhaled (*Closed Class*)
- Antihistamines Minimally Sedating
- Bronchodilators, Long Acting Beta Adrenergics
- Bronchodilators, Short Acting Beta Adrenergics
- COPD (*includes Anticholinergics, Bronchodilators and Phosphodiesterase 4 (PDE4) Inhibitors*) (*Closed Class*)
- Cough & Cold Agents (*Legend*)
- Intranasal Rhinitis (*includes Antihistamines and Corticosteroids*)
- Leukotriene Modifiers

Confidential Meeting (Pricing Information Discussion)

**P&T Committee, DMAS & MMS Staff
Pursuant to 42 USC §1396r-8**

PDL Recommendations and Vote

P&T Committee Members

Criteria Discussion of Phase II New Drugs*

P&T Committee Members **TAB 27**

Criteria Discussion of PDL Phase I Drug Classes*

P&T Committee Members

Next Meeting – tentatively scheduled for March 19, 2020

**Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*